Cargando…

Real‐world clinical outcomes of olaparib therapy in Chinese patients with advanced serous ovarian cancer treated in Macau

BACKGROUND: Olaparib has been approved as an active and maintenance therapy for patients with platinum‐sensitive, BRCA‐mutated high‐grade serous ovarian cancer (SOC). However, the efficacy and safety data is lack among Chinese ovarian cancer patients. AIM: This real‐world study aimed to evaluate the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Yabing, Chen, Hongtao, Huang, Yaobin, Hu, Hao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Clinical Study Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941423/ https://www.ncbi.nlm.nih.gov/pubmed/32721133 http://dx.doi.org/10.1002/cnr2.1180

Ejemplares similares

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer
por: Ledermann, Jonathan A, et al.
Publicado: (2016)

Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China
por: Ni, Jing, et al.
Publicado: (2019)

Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours
por: Del Conte, G, et al.
Publicado: (2014)

Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer
por: van der Noll, Ruud, et al.
Publicado: (2015)

Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study
por: Paik, E Sun, et al.
Publicado: (2019)

Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours
por: Dean, E, et al.
Publicado: (2012)

Profile of olaparib in the treatment of advanced ovarian cancer
por: Chase, Dana M, et al.
Publicado: (2016)

Selective Retina Therapy with Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients
por: Kim, Ye Ji, et al.
Publicado: (2018)

A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours
por: Khan, O A, et al.
Publicado: (2011)

Olaparib treatment in older patients with ovarian cancer: need for ‘real-world’ data beyond clinical trials
por: Liposits, Gabor, et al.
Publicado: (2020)

Macau's sustainability and diversification
por: Liu, Chengkun, et al.
Publicado: (2022)

The feasibility of smartphone-based application on cardiac rehabilitation for Chinese patients with percutaneous coronary intervention in Macau: a qualitative evaluation
por: Lao, Sarah Sio Wa, et al.
Publicado: (2022)

Olaparib in the management of ovarian cancer
por: Bixel, Kristin, et al.
Publicado: (2015)

Olaparib in Epithelial Ovarian Cancer
por: Anastasia, Paula J.
Publicado: (2016)

Olaparib and advanced ovarian cancer: Summary of the past and looking into the future
por: Maiorano, Brigida Anna, et al.
Publicado: (2023)

Surgical staging and prognosis in serous borderline ovarian tumours (BOT): A subanalysis of the AGO ROBOT study
por: Trillsch, F, et al.
Publicado: (2015)

Clinicopathological Characteristics and Her-2/neu Status in Chinese Patients with Uterine Papillary Serous Carcinoma
por: Ren, Yulan, et al.
Publicado: (2011)

Chinese Herbal Medicine Dingji Fumai Decoction for Ventricular Premature Contraction: A Real-World Trial
por: Liang, Bo, et al.
Publicado: (2020)

Mutation profiles in circulating cell‐free DNA predict acquired resistance to olaparib in high‐grade serous ovarian carcinoma
por: Hu, Dianxing, et al.
Publicado: (2022)

Retrospective efficacy analysis of olaparib combined with bevacizumab in the treatment of advanced colorectal cancer
por: Jiang, Yi-Ling, et al.
Publicado: (2023)

Real-World Use and Outcomes of Olaparib: a Population-Based Cohort Study
por: Eriksson, Irene, et al.
Publicado: (2018)

Management of the Elderly Patients with High-Grade Serous Ovarian Cancer in the REAL-WORLD Setting
por: Liontos, Michalis, et al.
Publicado: (2021)

Olaparib Monotherapy for BRIP1-Mutated High-Grade Serous Endometrial Cancer
por: Nakamura, Kohei, et al.
Publicado: (2020)

Survival of Advanced Stage High-Grade Serous Ovarian Cancer Patients in the Republic of Macedonia
por: Aluloski, Igor, et al.
Publicado: (2017)

Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes
por: Stumpf, M, et al.
Publicado: (2009)

Does world heritage list really induce more tourists? Evidence from Macau
por: Huang, Chia-Hui, et al.
Publicado: (2012)

Olaparib outcomes in metastatic castration-resistant prostate cancer: First real-world experience in safety and efficacy from the Chinese mainland
por: Pan, Jian, et al.
Publicado: (2022)

Real-world hematological adverse events in Chinese patients with advanced ovarian cancer treated with an individualized starting dose of niraparib
por: Wang, Junjian, et al.
Publicado: (2021)

Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk
por: Lampert, Erika J., et al.
Publicado: (2019)

Blood bioactive sphingolipids in patients with advanced serous epithelial ovarian cancer – mass spectrometry analysis
por: Knapp, Paweł, et al.
Publicado: (2018)

Outcome of R-CHOP or CHOP Regimen for Germinal Center and Nongerminal Center Subtypes of Diffuse Large B-Cell Lymphoma of Chinese Patients
por: Huang, Ying, et al.
Publicado: (2012)

Gender Differences in Pathways to Compulsive Buying in Chinese College Students in Hong Kong and Macau
por: Ching, Terence H. W., et al.
Publicado: (2016)

Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy
por: Friedlander, Michael, et al.
Publicado: (2018)

Recurrent uterine serous carcinoma with a germline pathogenic BRCA2 variant treated using olaparib: A case report
por: Inoue, Kayo, et al.
Publicado: (2020)

Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry
por: Jiménez Fonseca, Paula, et al.
Publicado: (2017)

Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study
por: Bellier, Charlotte, et al.
Publicado: (2023)

Real-World Experience with Dolutegravir-Based Two-Drug Regimens
por: Ward, Douglas, et al.
Publicado: (2020)

Gestational glucose intolerance and pregnancy outcomes: a retrospective study in the primary care setting of Macau
por: Lei, Sao Kuan, et al.
Publicado: (2023)

Tolerance of Olaparib in a Patient With Unresectable Serous Gynecologic Cancer and End-Stage Renal Disease
por: Goon, Kelsey C, et al.
Publicado: (2023)

Biguanides in combination with olaparib limits tumorigenesis of drug‐resistant ovarian cancer cells through inhibition of Snail
por: Wang, Qiong, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4k69r7eegqbt9jgtnliqr1eqkg